China firm to launch new prostate cancer Dx
This article was originally published in Clinica
Executive Summary
China Medical Technologies is to launch a new molecular diagnostic kit for prostate cancer in July 2008. The Prostate Cancer FISH (fluorescent in situ hybridization) Detection Kit detects TMPRSS2 and ETS gene fusions in prostate pathological tissues. Its methodology is based on research that shows these fusions to occur in approximately 80% of prostate cancer cases. This is said to indicate that the -application of TMPRSS2/ETS gene fusions as specific biomarkers can significantly increase the sensitivity for prostate cancer diagnosis", reports BioSpectrum Bureau.